NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc. today announced that a feasibility study is underway at Massachusetts General Hospital in Boston to determine the initial safety and efficacy of its Lumicell System for in vivo imaging of metastases to the peritoneum from primary ovarian cancer, appendiceal cancer, gastrointestinal cancer and mesothelioma.
The feasibility study is being conducted by Massachusetts General Hospital investigator Dr. James Cusack, MD. Dr. Cusack heads the Cusack Laboratory at Massachusetts General Hospital, which focuses on advancing cancer treatment resistance and the development of new targeted therapies to improve cancer patient survival. This application was developed in his laboratory and the promising results were published in 2017 in Annals of Surgical Oncology.1 He is the Director of the Peritoneal Surface Malignancy Program at the hospital as well as an Associate Professor of Surgery at Harvard Medical School. Dr. Cusack began using the Lumicell System for the study with the first patient’s surgical procedure on April 3, 2019.
“This feasibility study is a critical first step in determining if the Lumicell System will be effective in improving quality of life for people with peritoneal metastases and ovarian cancer,” said Dr. Cusack. “We will be evaluating the Lumicell System, by comparing the imaging results detected at the molecular level with the traditional microscopic evaluation, to improve surgical outcomes for patient with peritoneal surface malignancies.”
More than 225 participants have been treated with the Lumicell System in clinical trials. The majority of these participants are women undergoing lumpectomy for breast cancer. Dr. Barbara Smith, MD, PhD, Director of the Breast Program at Massachusetts General Hospital and Professor of Surgery at Harvard Medical School is the lead investigator of the breast cancer trials. Dr. Smith reported positive clinical results in 2018 using Lumicell technology during breast cancer surgery — demonstrating rapid and direct identification of residual tumor in lumpectomy cavities during breast cancer surgery.
“Our study found that the Lumicell Imaging System was effective for real time identification of residual cancer intraoperatively. This is an important advance as many breast cancer patients currently need second surgeries for positive margins,” said Dr. Smith. “We’re excited to determine whether this peritoneal feasibility study will bring the same advantages to treating patients with peritoneal metastases — with an ultimate goal to improve survival rates.”
Since 2003, Lumicell has been dedicated to developing technology to overcome limitations in detecting all cancer cells that are notoriously evasive and cannot be seen with the naked eye. The Lumicell System enables surgeons to visualize and distinguish cancer cells from healthy cells, so tumor cells aren’t left behind during the first surgery.
“We are very excited to have our solution support surgeons and patients in breast, ovarian/peritoneal and five other cancers in clinical trials at this time,” said Kelly Londy, Chief Executive Officer of Lumicell. “Because of this work, we’re one step closer to delivering on our promise: developing the technology that visualizes cancer cells in real-time during surgery and helps to improve and save lives. Our team is very hopeful that the outcome of the feasibility study will reveal the positive results that our industry, doctors, and patients are waiting for.”
For more information on Lumicell clinical trials, visit the Clinical Trials page of the Lumicell website.
About Lumicell,
Inc.
Lumicell is a technology leader in the field of
image-guided cancer surgery. The company is developing a novel system
that enables real-time detection of tumor tissue in patients so that no
cancer cells are left behind during surgery. The company’s Lumicell
System has unprecedented ability to see and remove cancer cells
remaining in the surgical cavity – beyond the margin of the specimen –
and has the potential to significantly improve surgical outcomes and
reduce healthcare costs by eliminating the need for repeat surgeries.
Lumicell is investigating the Lumicell System in patients undergoing
surgery for breast cancer, appendiceal cancer, mesothelioma, ovarian
cancer, prostate cancer, brain cancer, colorectal, esophageal and
pancreatic cancers. Additional future indications are planned to include
perfusion, wound care and infection, and surgeries for lung, and liver
cancers. For more information, please visit www.lumicell.com.
1. Chan CHF, Liesenfeld LF, Ferreiro-Neira I, Cusack JC. Preclinical evaluation of cathepsin-based fluorescent imaging system for cytoreductive surgery. Ann Surg Onc, 2017 Apr 24(4):931-38
